INFORMATION INTENDED FOR GLOBAL HEALTHCARE PROFESSIONALS

Healthcare Professionals

GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics through our proven drug discovery and development processes, our intellectual property portfolio and our regulatory and manufacturing expertise. GW’s research explores the potential therapeutic application of cannabinoids and we have evaluated the pharmacology of a number of cannabinoids across a wide range of disease areas.

Our primary focus is on disorders of the central nervous system (CNS), including epilepsy. Our lead cannabinoid product is a liquid formulation of highly purified plant-derived cannabidiol, or CBD, (Epidiolex® in the United States). In June 2018, the FDA approved Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome, two rare and particularly difficult to treat forms of epilepsy. The product was launched in November 2018 and is now available by prescriptions in the U.S.

We commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States. GW is in the process of working with the FDA to identify the optimal path to NDA submission for Sativex in the U.S.

We have a deep pipeline of additional cannabinoid product candidates which include compounds in development for epilepsy, autism spectrum disorders, glioma and schizophrenia.

GW is in a unique position to develop and manufacture plant-derived cannabinoid formulations worldwide at sufficient quality, uniformity and scale for the purposes of pharmaceutical development and to meet international regulatory requirements.

PRODUCTS

Cannabidiol (CBD) Oral Solution

Now approved as Epidiolex in the United States; an investigational drug not approved for use by any other national regulatory agency.

US Residents, click here

Sativex® (nabiximols)

Sativex is a cannabinoid medicine for the treatment of multiple sclerosis spasticity.

Learn more

RECENT PIPELINE NEWS

Nov 06, 2018
LONDON , Nov. 06, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 27 November, 2018 its
Nov 01, 2018
- Medication indicated for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, two rare, severe childhood-onset epilepsies - - Comprehensive support program available for eligible patients - LONDON and CARLSBAD, Calif., Nov.
Oct 05, 2018
LONDON and CARLSBAD, Calif. , Oct. 05, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today